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Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen
Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
A Randomized Clinical Trial
Ulka N. Vaishampayan, MD; Lance K. Heilbrun, PhD; Paul Monk III, MD; Sheela Tejwani, MD; Guru Sonpavde, MD; Clara Hwang, MD; Daryn Smith, MS; Pallavi Jasti, MD;
Kimberlee Dobson, BS; Brenda Dickow, RN; Elisabeth I. Heath, MD; Louie Semaan, BS; Michael L. Cher, MD; Joseph A. Fontana, MD; Sreenivasa Chinni, PhD

Abstract

Key Points

IMPORTANCE Black patients have been underrepresented in prospective clinical trials of advanced
prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with
planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer
(mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT).

Question Is enzalutamide combined
with androgen deprivation therapy
associated with better outcomes than
treatment with bicalutamide in Black
men with metastatic hormone-sensitive

OBJECTIVE To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in

prostate cancer (mHSPC)?
Findings In a randomized clinical trial of

men with mHSPC, with a subset analysis of Black patients.

71 men with mHSPC, the 7-month

DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, a phase 2 screening design

prostate-specific antigen response rate

enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified

was significantly improved with

by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was

enzalutamide vs bicalutamide among

required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no

Black patients but not among non-Black

history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was

patients.

performed from February 2019 to March 2020.

Meaning These findings suggest that
treatment with enzalutamide is

INTERVENTIONS Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or
bicalutamide (50 mg daily) in addition to ADT.

associated with improved outcomes vs
bicalutamide in Black men with mHSPC,
and incorporation of enzalutamide in

MAIN OUTCOMES AND MEASURES The primary end point was the 7-month prostate-specific
antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS)

the mHSPC treatment plan should be
strongly considered.

outcome. Secondary end points included adverse reactions, time to PSA progression, and OS.
RESULTS A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were
Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive
enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone
pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%;
95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking
bicalutamide (P = .008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was

+ Visual Abstract
+ Invited Commentary
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among
those taking bicalutamide (P = .009); among non-Black patients, the SMPR was 94% (95% CI,
74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking
bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with
bicalutamide.
CONCLUSIONS AND RELEVANCE The findings of this randomized clinical trial comparing
enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes
(continued)
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Abstract (continued)

compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients
with mHSPC.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02058706
JAMA Network Open. 2021;4(1):e2034633.
Corrected on February 25, 2021. doi:10.1001/jamanetworkopen.2020.34633

Introduction
Androgen deprivation therapy (ADT) has been the backbone of systemic therapy in advanced
prostate cancer. Standard therapy consists of testosterone suppression in combination with
bicalutamide, which is a nonsteroidal androgen receptor antagonist. Enzalutamide is a secondgeneration androgen receptor inhibitor that shows enhanced cytotoxic effects in prostate cancer
cells by blocking nuclear translocation and DNA binding.1 Compared with bicalutamide, enzalutamide
has demonstrated superior progression-free survival in metastatic castrate-resistant prostate cancer
(mCRPC).2 This study was designed to evaluate the clinical efficacy of enzalutamide vs bicalutamide
in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC).
Multiple ways of enhancing and optimizing therapy in hormone-sensitive disease have now
been reported. The CHAARTED trial3 reported an overall survival (OS) advantage with the addition
of docetaxel chemotherapy to ADT in patients with mHSPC. The STAMPEDE4 and LATITUDE5 studies
proved the OS benefit of adding abiraterone and prednisone to ADT in patients with metastatic or
high-risk prostate cancer. Recently, the TITAN6 trial affirmed the benefit of early apalutamide
therapy. The addition of enzalutamide also reported proven efficacy in the ENZAMET7 and ARCHES8
trials. In summary, early intensification with the addition of an androgen receptor axis targeted
(ARAT) agent, or docetaxel, demonstrated improved efficacy in mHSPC.
Although all these studies showed significant benefits, the populations enrolled were
predominantly White. Black patients with advanced prostate cancer have specific nuances of
presentation, prognosis, and therapy outcomes. Emerging data from population cohorts in the
Veterans Affairs Health System revealed that Black men with prostate cancer have similar OS with the
addition of docetaxel or abiraterone.9 The disparities in clinical outcomes, however, have not been
prospectively evaluated in mHSPC. We conducted a randomized clinical trial evaluating clinical
outcomes with early intensification of therapy in mHSPC and the impact on clinical outcomes in
White and Black patients with prostate cancer.
Prostate cancer has a higher mortality rate among Black men compared with White men. A
recent report9 reviewing the Veterans Affairs health database reported that Black men were younger
and had higher prostate-specific antigen (PSA) levels but demonstrated no differences in 10-year
prostate cancer–specific mortality. In metastatic prostate cancer, there appear to be differences in
outcomes even when access to care is controlled, such as within a clinical trial patient population.10
The controversy is whether this disparity is explained by genetic or socioeconomic factors.
Retrospective studies are confounded by multiple competing factors. Black patients are grossly
underrepresented in prospective trials of advanced prostate cancer. The enrollment of Black patients
was 10% in the CHAARTED3 trial and 12% in the SWOG 9346 trial.11 The ARCHES8 trial enrolled only
8 Black patients (1.4%) in each group, and no Black patients were enrolled in the TITAN6 and
ENZAMET7 trials. Given the potential for racial disparity in prostate cancer outcomes and the
underrepresentation of Black men in mHSPC clinical trials, the current study design required at least
30% enrollment of Black patients. The primary goal of this study was to compare the clinical
outcomes with enzalutamide and bicalutamide in the mHSPC disease state, evaluating the
differences in efficacy by race and exploring biomarkers associated with therapeutic resistance.
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Methods
Study Design
The primary objective of this randomized clinical trial was to evaluate the 7-month PSA response
(SMPR) rate in each group, because this has been reported to be a surrogate for OS in mHSPC.11 The
secondary objectives were to evaluate the clinical safety, progression-free survival, time to PSA
progression (TTPP), and OS, and to examine the associations of clinical outcomes with race and
tissue biomarkers. This was a multicenter, open-label 1:1 randomized trial of enzalutamide at the
starting dose of 160 mg (4 capsules of 40 mg each) orally daily vs bicalutamide 50 mg orally daily.
Luteinizing hormone releasing hormone (LHRH) analogue therapy was administered in both groups.
The study was approved by the Wayne State University institutional review board, and written
informed consent was obtained from all patients before registration. Race was self-reported by
patients and documented. This study follows the Consolidated Standards of Reporting Trials (CONSORT)
reporting guideline. The trial protocol is provided in Supplement 1.
The primary objective of the study was to compare the rates of achieving PSA response at
month 7 (SMPR) by treatment group with LHRH analogue therapy and enzalutamide vs LHRH
analogue and bicalutamide. Secondary objectives included comparing the primary end point by race
(Black vs non-Black), response rates, and adverse reactions in each group, and time to event end
points (TTPP and OS) by treatment group and by race. The open-label study used a randomized
phase 2 screening design, as described by Rubinstein et al.12 This enabled a nondefinitive comparison
of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain
(present or absent) and were randomized within each of 4 strata. The randomization sequences
consisted of random permuted blocks of varying sizes.

Patient Selection
Eligible patients were aged 18 years or older, with histologically confirmed prostate adenocarcinoma
with radiological evidence of metastases. Late induction was permitted within 3 months of starting
LHRH analogue therapy or antiandrogen. A minimum PSA level of 4 ng/mL (to convert to micrograms
per liter, multiply by 1) was required. Patients with a performance status score of 2 or less and life
expectancy of 6 months or more were eligible. Patients were required to have adequate bone
marrow, liver, and renal function. Patients with a history of neoadjuvant or adjuvant hormone
therapy were eligible if they had received it for a duration of 24 months or less, consisting of ADT
(single-agent LHRH or combination treatment with nonsteroidal androgen receptor inhibitors,
excluding orchiectomy). Patients had to be not receiving ADT for at least 6 months before
registration. No prior chemotherapy or ARAT agents were allowed. Concomitant radiation therapy
was allowed for the palliation of severe pain or neuropathic compression. The study allowed a
maximum of 2 dose reductions of enzalutamide to 120 mg and 80 mg orally daily, respectively. If
grade 3 or 4 adverse reactions or grade 2 adverse reactions lasting for 7 days or longer were noted,
then medication was held until the adverse reaction resolved to grade 1 or baseline. Dose reduction
could be considered when resuming therapy. If an adverse reaction persisted after 2 dose reductions
and optimal supportive care, then enzalutamide therapy had to be discontinued. Patients with
history of seizures, risk factors for seizure, grade 3 or 4 congestive heart failure, or myocardial
infarction were excluded. After the CHAARTED trial3 results, the study eligibility was modified to
include patients with at least 1 of the following: low-volume disease (defined as no visceral
metastases and <4 bone metastases), not candidates for docetaxel-based chemotherapy, or refused
docetaxel chemotherapy.

Tissue Biomarker Studies
Biopsy Tissue Procurement and Analysis
Metastatic biopsy collection was performed by a radiologist in the operating room. From each patient
1 to 3 cores were collected in a vial and flash frozen in liquid nitrogen, and another 1 to 2 cores were
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collected in 10% phosphate-buffered saline formaldehyde solution. Formalin-fixed bone biopsy
tissues were decalcified in 10% EDTA solution before embedding in paraffin, whereas lymph node
biopsy tissues were embedded after formalin fixation. Immunohistochemical analysis with
pan-cytokeratin antibody was performed on paraffin-embedded tissue sections, and a pathologist
assessed the tumor cell content in tissue sections. Tumor tissue biopsies positive for cytokeratinexpressing tumor cells were further processed for RNA extraction and quantitative polymerase chain
reaction analysis.
Gene Expression Analysis
Frozen biopsy tissues were thawed and homogenized in a Precellys 24 tissue homogenizer (Bertin
Instruments) in Trizol solution. RNA was extracted and quantitated with an Epoch microplate
spectrophotometer from BioTek (ThermoFisher Scientific). One microgram of RNA was used for
cDNA synthesis using a SuperScript First-strand synthesis kit (Invitrogen). Quantitative polymerase
chain reaction analysis was performed with primers against ERG, CXCR4, and AKR1C3 using methods
described elsewhere (eFigure in Supplement 2).13,14 For absolute quantitation of gene expression in
tumor tissue samples, first the standard curves were generated using plasmids harboring cDNA of
genes in quantitative polymerase chain reaction (eFigure in Supplement 2). Using the standard
curves, the copy numbers of gene expressed in tumor tissues were determined by extrapolating the
cDNA copy number from tumor tissue circulating tumor values of genes of interest, as previously
described.15

Statistical Analysis
Statistical study design assumptions were (1) the proportion of patients achieving (and then
sustaining) PSA level less than or equal to 4.0 ng/mL within 7 months of starting therapy (ie, the
SMPR rate while taking bicalutamide) would be 50%; (2) the hypothesized SMPR rate while taking
enzalutamide would be 75%; (3) α = .10 (1-sided); (4) power = 0.80; and (5) balanced 1:1
randomization. Those assumptions would require 41 patients per group (total of 82 patients), as
calculated from the nQuery Advisor statistical software version 7.0 (Statsols). Accrual was halted
after changes in standard of care. Hence, this report contains results for 71 accrued patients.
SMPR rates were compared using Fisher exact test, and 2-sided 95% CIs were calculated using
the Wilson score method. TTPP and OS distributions were estimated with standard Kaplan-Meier
methods. Median follow-up for TTPP, and separately for OS, was calculated using the reverse KaplanMeier method. Kaplan-Meier distributions were compared using stratified log-rank tests. The hazard
ratio (HR) for PSA progression and its 2-sided 95% CI were derived from a Cox proportional hazards
model. The HR for death (and its 2-sided 95% CI) was also derived from a Cox proportional hazards
model. The proportional hazards assumption was checked by examining log(−log) plots and
Epanechnikov smoothed hazard functions. Simultaneous comparison of 4-group (group by race)
TTPP and of OS were followed by comparison of all 6 pairs of group and race subgroups. This created
a multiple comparisons problem due to the resulting test multiplicity. To control the overall type 1
error rate (α) for the entire set of 6 comparisons, the Benjamini-Hochberg false discovery rate
procedure, with a false discovery rate of 0.05, was used. Data analysis was performed using SAS
statistical software version 9.4 (SAS Institute) from February 2019 to March 2020.

Results
Patient Characteristics and Adverse Reactions
A total of 71 men were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian
(Figure 1). The median (range) age was 65 (51-86) years (Table 1). Thirty-six patients were
randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. The study
characteristics were well balanced between the 2 groups. The median (range) baseline PSA level was
56.3 ng/mL (4.2-10 431 ng/mL) in the enzalutamide group and 60 ng/mL (4.9-12 030 ng/mL) in the
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bicalutamide group. Twenty-six patients (37%) had bone pain, which is known to be associated with
shorter survival outcome in patients with advanced prostate cancer. Forty-eight patients (68%) were
late induction, 37 (52%) had extensive disease with 4 or more metastatic lesions, and 3 (4%) had
visceral metastases. Predominant grade 3 adverse events in the enzalutamide group were
hypertension in 3 patients and syncope in 2 patients (eTable in Supplement 2). One patient in the
enzalutamide group had a seizure, and the medication was permanently discontinued. In the
bicalutamide group, 1 patient had grade 3 hypertension and 2 patients had grade 3 fatigue. No grade
4 treatment-related adverse reactions were noted. No unexpected adverse reactions or treatment
related mortality were noted.

Figure 1. Study Recruitment Flowchart
93 Patients assessed for eligibility
22 Excluded
19 Not meeting inclusion
criteria
3 Refused to participate

71 Patients randomized

36 Allocated to enzalutamide group
35 Received allocated intervention
1 Did not receive allocated
intervention

35 Allocated to bicalutamide group
34 Received allocated intervention
1 Did not receive allocated
intervention

23 Discontinued intervention
9 Died
13 Patients on follow-up
1 Patient withdrawn
13 Still receiving treatment

34 Discontinued intervention
18 Died
15 Patients on follow-up
1 Patient withdrawn
1 Still receiving treatment

36 Analyzed (by intention to treat)

35 Analyzed (by intention to treat)

Table 1. Patient Characteristics by Treatment Group
Patients, No. (%)
Characteristic

Total
(N = 71)

Enzalutamide
(n = 36)

Bicalutamide
(n = 35)

Age, median (range), y

65 (51-86)

66 (54-86)

63 (51-84)

Black race

29 (41)

15 (42)

14 (40)

Yes

26 (37)

14 (39)

12 (34)

No

45 (63)

22 (61)

23 (66)

3 (4)

1 (3)

2 (5)

0

32 (45)

16 (44)

16 (45)

1

39 (55)

20 (56)

19 (54)

Bone metastases only

59 (83)

31 (86)

28 (80)

Extensive disease (≥4 lesions)

37 (52)

20 (56)

17 (49)

Oligometastatic disease (<4 lesions)

34 (48)

16 (44)

18 (51)

Bone pain

Lung or liver metastases
Performance status score

Measurable disease

34 (48)

17 (47)

17 (48)

Late induction

48 (68)

26 (72)

22 (63)

JAMA Network Open. 2021;4(1):e2034633. doi:10.1001/jamanetworkopen.2020.34633 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 02/25/2021

January 26, 2021

5/11

JAMA Network Open | Oncology

Enzalutamide vs Bicalutamide Plus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer

Efficacy
Seven-Month PSA Response Rate
The SMPR end point is reported for 58 patients because 13 of the 71 patients enrolled did not have a
month 7 PSA value. However, by the intention to treat principle, all 71 patients randomized are
included in the analysis of clinical end points such as TTPP and OS. Waterfall plots in Figure 2A and 2B
show PSA decreases for all patients. All 71 patients are included in the Kaplan-Meier graphs of TTPP
and OS by therapy group (36 taking enzalutamide and 35 taking bicalutamide), and in the KaplanMeier graphs of TTPP and OS by race (42 non-Black and 29 Black). SMPR was achieved in 30 of 32
patients (94%; 95% CI, 80%-98%) taking enzalutamide and in 17 of 26 patients (65%; 95% CI,
46%-81%) taking bicalutamide (P = .008) (difference, 29%; 95% CI, 5%-50%) (Table 2). The Black
patients had an increased likelihood of benefit with enzalutamide compared with bicalutamide, with
SMPRs of 13 of 14 patients (93%; 95% CI, 69%-99%) and 5 of 12 patients (42%; 95% CI, 19%-68%),
respectively (P = .009). The non-Black patients had comparable SMPR rates of 17 of 18 patients
(94%; 95% CI, 74%-99%) taking enzalutamide and 12 of 14 patients (86%; 95% CI, 60%-96%)
taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with
bicalutamide.

Figure 2. Prostate-Specific Antigen (PSA) Response, Time to PSA Progression, and Survival by Treatment Group
A PSA response with enzalutamide

B

Time to PSA progression
1.0

100

Cumulative proportion
PSA progression-free

Change in PSA level
from baseline to 7 mo, %

Log-rank P <.001
50

0

–50

0.8
Enzalutamide
0.6
0.4
0.2
Bicalutamide
0

–100
0

5

10

15

20

25

30

0

35

12

24

36

48

60

1

0

Time since PSA nadir, mo

Rank of percentage change
No. at risk
Bicalutamide
Enzalutamide

C

5
14

1
4

0
3

D Overall survival

PSA response with bicalutamide

1.0

Cumulative proportion surviving

120
80

Change in PSA from
baseline to 7 mo, %

35
36

40
0
–40
–80

Log-rank P =.002
0.8
Enzalutamide
0.6
0.4
0.2
Bicalutamide
0

–120
0

5

10

15

20

25

0

30

12

24

36

48

60

1
3

0
1

Time since registration, mo

Rank of percentage change
No. at risk
Bicalutamide
Enzalutamide

Waterfall plots show PSA response with enzalutamide (A) and bicalutamide (C). In the
waterfall plots, circles above the lines indicate nadir PSA level less than or equal to 4.0
ng/mL (to convert to micrograms per liter, multiply by 1). Panel B shows time to PSA

35
36

25
34

14
21

4
9

progression. Panel D shows overall survival by treatment group. In B and D, vertical hash
marks denote data censoring.
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Time to Event End Points
Of the 71 patients, as of this writing, only 20 have had PSA progression, for an event proportion of
28%. Twenty-six (37%) deaths have occurred. This indicates immature TTPP and OS data, and
follow-up is ongoing. The median (range) follow-up for TTPP was 8.6 (0.2-48.1) months. The median
(range) follow-up for OS was 39.0 (0.4-60.7) months. Enzalutamide therapy significantly improved
TTPP (HR, 0.15; 95% CI, 0.05-0.47; P < .001) and OS (HR, 0.31; 95% CI, 0.13-0.74; P = .002)
(Figure 2C and 2D). TTPP did not differ significantly by race (HR for Black patients, 1.85; 95% CI, 0.774.47; P = .16) (Figure 3A). Also, OS did not differ significantly by race (HR for Black patients, 1.24;
95% CI, 0.56-2.72; P = .60) (Figure 3B). TTPP did not differ significantly by baseline bone pain status
(P = .43; log-rank χ 12 = 0.63).
The overall difference in TTPP across the 4 groups of group and race combinations appeared to
be clinically meaningful, and was significant (P < .001; log-rank χ 32 = 17.78) (Figure 3C). That finding
does not identify which subgroups differed from each other. Comparison of all 6 pairs of subgroups
was then required, while also controlling for the resulting test multiplicity. That was done using the
Benjamini-Hochberg false discovery rate procedure, which revealed that only 2 subgroup

Table 2. The Primary End Point of SMPR Rate With Baseline Patient and Disease Characteristics Subgroups and Tissue Biomarker Data
Enzalutamide (n = 36)b

Bicalutamide (n = 35)c

Patients,
No. (%)

Total (N = 71)a
SMPR rate, patients,
No. (%)

Patients,
No. (%)

SMPR rate, patients,
No. (%)

Patients,
No. (%)

SMPR rate, patients,
No. (%)

<70

34 (59)

27 (79)

19 (59)

18 (95)

15 (58)

9 (60)

≥70

24 (41)

20 (83)

13 (41)

12 (92)

11 (42)

8 (73)

Black

26 (43)

18 (69)

14 (44)

13 (93)

12 (46)

5 (42)

Non-Black

32 (57)

29 (91)

18 (56)

17 (94)

14 (54)

12 (86)

Yes

20 (34)

13 (65)

11 (34)

9 (82)

9 (35)

4 (44)

No

38 (66)

34 (89)

21 (66)

21 (100)

17 (65)

13 (76)

≥8

40 (73)

32 (80)

23 (77)

21 (91)

17 (68)

11 (65)

<8

15 (27)

12 (80)

7 (23)

7 (100)

8 (26)

5 (63)

Visceral

3 (5)

3 (100)

1 (3)

1 (100)

2 (8)

2 (100)

Lymph node

22 (38)

18 (82)

11 (34)

11 (100)

11 (42)

7 (64)

Bone only

25 (43)

19 (76)

17 (53)

15 (88)

8 (31)

4 (50)

Other

8 (13)

7 (88)

3 (9)

3 (100)

5 (19)

4 (80)

0

27 (47)

25 (93)

15 (47)

15 (100)

12 (46)

10 (83)

1

31 (53)

22 (71)

17 (53)

15 (88)

14 (54)

7 (50)

Characteristic
Age, y

Race

Bone pain

Gleason score

Sites of metastases

Performance status score

ERG level
Less than or equal to the median

22 (49)

19 (86)

10 (48)

10 (100)

12 (50)

9 (75)

Greater than the median

23 (51)

18 (78)

11 (52)

11 (100)

12 (50)

7 (58)

CXCR4 level
Less than or equal to the median

22 (49)

19 (83)

10 (48)

10 (100)

12 (50)

9 (75)

Greater than the median

23 (51)

18 (78)

11 (52)

11 (100)

12 (50)

7 (58)

AKR1C3 level
Less than or equal to the median

22 (49)

19 (86)

10 (48)

10 (100)

12 (50)

9 (75)

Greater than the median

23 (51)

18 (78)

11 (52)

11 (100)

12 (50)

7 (58)

Abbreviations: PSA, prostate specific antigen; SMPR, 7 month PSA response rate.
a

Not all patients with a 7-month PSA value had biomarker data. Also, not all patients
with biomarker data had a 7-month PSA value. Thus, only 58 patients had SMPR data
available. For all 71 patients (median [range] age, 66 [51-86] years), the SMPR rate was
81.0% (95% CI, 69.2%-89.1%).

b

For the enzalutamide group (median [range] age, 67 [54-86] years), the SMPR rate was
93.8% (95% CI, 79.9%-98.3%).

c

For the bicalutamide group (median [range] age, 64 [51-84] years), the SMPR rate was
65.4% (95% CI, 46.2%-80.6%).
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comparisons were still significant using a false discovery rate of 0.05: the enzalutamide-treated
non-Black patients had significantly longer TTPP than did the bicalutamide-treated non-Black
patients (Benjamini-Hochberg adjusted P = .002; log-rank χ 12 = 13.21), and the enzalutamide-treated
Black patients had significantly longer TTPP than the bicalutamide-treated Black patients
(Benjamini-Hochberg adjusted P = .005; log-rank χ 12 = 9.79).
Somewhat similar subgroup comparison results were observed for OS (Figure 3D). Among
non-Black patients, OS was significantly longer in the enzalutamide group than in the bicalutamide
group (Benjamini-Hochberg adjusted P = .004; log-rank χ 12 = 11.62). Also, OS was significantly longer
for enzalutamide-treated non-Black patients than for bicalutamide-treated Black patients (adjusted
P = .04; log-rank χ 12 = 6.30).
Biomarkers
Of the 71 enrolled patients, 53 biopsy samples (75%) had tumor tissue available. Of these, the
biomarkers were measurable in 45 samples. TMPRSS-ERG fusion gene, CXCR4, and androgen
biosynthetic enzyme AKR1C3 levels were determined in metastatic biopsies (eFigure in
Supplement 2). Patients in the bicalutamide group with a low copy number of ERG, CXCR4, or AKR1C3
had a higher SMPR (9 of 12 patients [75%]) compared with those with a high copy number (7 of

Figure 3. Prostate-Specific Antigen (PSA) Response, Time to PSA Progression, and Survival by Treatment Group and Race
A Time to PSA progression by race
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12 patients [58%]) (Table 2). However, no differences in SMPR were noted by race in the
enzalutamide group, because both groups had almost 100% incidence rates. Black patients with high
levels of ERG, CXCR4, or AKR1C3 demonstrated a numerically lower likelihood of achieving SMPR
compared with non-Black patients (67% vs 92%).

Discussion
To our knowledge, this is the only randomized clinical trial comparing bicalutamide with enzalutamide
in a Black patient population. The study results reveal that Black patients treated with bicalutamide had
a lower likelihood of biochemical response than the non-Black patients (42% vs 86%). The SMPR in
Black and non-Black patients taking enzalutamide therapy were comparable (93% vs 94%). Enzalutamide demonstrated a greater magnitude of improvement over bicalutamide, in the rate and duration
of PSA response in Black patients. ADT plus bicalutamide is inadequate therapy in all cases, but especially for Black patients. The addition of enzalutamide therapy resulted in outcomes for Black patients
comparable to those for non-Black patients. Retrospective studies16-18 have demonstrated racial differences in the efficacy of ARAT therapies. A matched case-control study16 led by Duke investigators confirmed that abiraterone and prednisone therapy improved PSA response rates and progression-free
survival in Black patients compared with White patients with mCRPC. Another retrospective study17
showed that the addition of abiraterone and prednisone, or enzalutamide, resulted in Black patients
having improved OS (HR, 0.887). Multivariable retrospective analysis18 of registry data evaluating
sipuleucel-T therapy in mCRPC revealed that Black race was significantly associated with longer OS outcomes. The current study confirms that the racial differences in bicalutamide efficacy are overcome by
using contemporary ARAT such as enzalutamide in advanced prostate cancer.
We explored the underlying molecular mechanisms that may be potential reasons for the
differences in responses. TMPRSS-ERG fusion gene expression is highly prevalent in patients with
prostate cancer.19 We have previously shown that a prometastatic gene CXCR420 and an androgen
biosynthetic enzyme AKR1C321 are downstream-regulated genes of TMPRSS2-ERG fusions in prostate
cancer cells. High baseline ERG levels and changes in androgen metabolism enzymes and resistance
pathways such as CXCR4 maybe potential molecular basis for the noted differences. Further
investigations exploring molecular biomarkers to help guide therapy are highly recommended.

Limitations and Strengths
Study limitations included the need to administratively close the study to accrual slightly short of the
target sample size. That decision was essential after a phase 3 trial5 demonstrated that abiraterone
and prednisone improved OS in mHSPC. We could no longer ethically randomize patients to
bicalutamide. The impact of that decision on our study’s results and conclusions is minimal, and any
small loss of statistical power is unimportant because a significant difference in favor of the
enzalutamide group was still observed. A second study limitation is the immature time to event data,
with event rates of 28% for TTPP and 37% for death.
Study strengths include the prospective nature of our study, the stratification by race, and the
accrual of 41% Black patients. Cumulatively, these factors make the study conclusions meaningful for
clinical application.

Conclusions
In this study, Black men with mHSPC had a decreased response rate with ADT and bicalutamide. The
incorporation of enzalutamide in mHSPC therapy overcame the disparity in biochemical response
rate and OS outcomes between Black and non-Black patients. The regimen was well tolerated, and
the favorable risk benefit profile makes it crucial to strongly consider the addition of enzalutamide to
ADT in Black patients with mHSPC.
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